|
|
|
|
 |
FDA Grants Invitrogen Premarket Approval of Breast Cancer Test |
| Companies mentioned in this article: |
|
Invitrogen |
|
| 7/8/2008 @ 7:42 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Invitrogen Corporation, (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced it has received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its SPOT-Light HER2 CISH Kit, indicated as an aid in the assessment of breast cancer patients for whom trastuzumab (Herceptin ) treatment is being considered. The approval marks the first PMA that Invitrogen has received from the FDA.
“The introduction of the SPOT-Light HER2 CISH Kit is another example of how Invitrogen technologies can be used in a clinical setting to have a direct impact on healthcare,” said Greg Lucier, Chairman and Chief Executive Officer of Invitrogen. “The FDA’s approval of this kit for the U.S. market also demonstrates our ability to apply Invitrogen technologies into high-growth applied markets.”
The kit is based on a technology called chromogenic in situ hybridization (CISH). The test uses a DNA probe for the HER2 gene, which is amplified in 18 to 30 percent of breast cancers and predicts whether a breast cancer patient is a candidate for trastuzumab treatment. Current medical practice requires that all patients who are considered for trastuzumab treatment be tested for HER2 amplification or overexpression. CISH test results are visualized under a standard bright-field microscope, as opposed to fluorescent in situ hybridization tests, in which the results must be visualized using a fluorescent microscope. This specialized microscope frequently requires that the analysis is done at a reference lab. In addition, HER2 CISH test results are quantifiable; removing the subjectivity inherent in tests based on immunohistochemistry (IHC) interpretation schemes.
“The current protocol for assessing HER2 gene status is for labs to initially screen tissue samples with immunohistochemistry to gauge whether there is an overabundance of the HER2 protein, as an indirect measure of gene amplification,” said August Sick, vice president and general manager of Invitrogen’s Cellular Analysis Business. “In the case of an inconclusive test, the samples are typically sent to an outside lab for confirmation. Because the SPOT-Light HER2 CISH Kit doesn’t need specialized equipment, any histology lab can now assess amplification of the HER2 gene while simultaneously examining tissue morphology.”
"Given the emerging potential use of trastuzumab in the adjuvant setting, the need to accurately determine the front-line HER2 status in breast cancer has never been more critical,” said Jeffrey Ross, M.D., Cyrus Strong Merrill Professor and Chair, Department of Pathology and Laboratory Medicine, Albany Medical College. “The CISH method has shown a high concordance with fluorescent in situ hybridization (FISH)-based assays for the identification of HER2 gene amplification, now considered the standard for confirming eligibility to receive the drug. Testing for HER2 status in breast cancer by CISH takes advantage of the best attributes of FISH using familiar, fast and low cost IHC detection techniques. This is a true marriage between the two procedures."
The SPOT-Light HER2 CISH Kit will be available in the U.S. in mid-August.
About Invitrogen
Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com. |
| BioTech / BioMedical / Medical |
|
|
| |
| Friday, October 3, 2008 |
 |
|
Essentialis Announces Two Presentations at Upcoming Conferences Posted 6:19 AM PST
|
| |
| Thursday, October 2, 2008 |
|
|
SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis Posted 1:08 PM PST
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain Posted 10:41 AM PST
|
| |
| Wednesday, October 1, 2008 |
|
|
TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel Posted 6:07 PM PST
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society Posted 6:04 PM PST
University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia Posted 3:52 PM PST
BioMed Realty Trust Announces Public Offering of 7,500,000 Shares of Common Stock Posted 3:51 PM PST
SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification. Posted 3:48 PM PST
Halozyme Therapeutics to Host Research Day for Investors and Analysts Posted 3:46 PM PST
Bio-Matrix Scientific Group, Inc. Receives and Processes First Cord Blood Specimens as Part of the Company’s Quality Assurance Program Posted 7:15 AM PST
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference Posted 4:33 AM PST
|
| |
| Tuesday, September 30, 2008 |
|
|
Genoptix Announces Participation at the Second Annual William Blair Small Cap Growth Conference Posted 10:15 AM PST
Cytori Receives Key Patent for its Cosmetic & Reconstructive Surgery Product Posted 7:54 AM PST
|
| |
| Monday, September 29, 2008 |
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference Posted 4:46 PM PST
Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting Posted 8:43 AM PST
Bio-Quant Announces the Expansion of Its Research Animal Diagnostic Services to Cover All Nine Species Posted 8:27 AM PST
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer Posted 8:09 AM PST
ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008 Posted 7:44 AM PST
|
| |
| Thursday, September 25, 2008 |
|
|
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds Posted 9:18 AM PST
CytRx Corporation to Present New Data from Its Proprietary Molecular Chaperone Drug Discovery Technology at the San Diego LEADS Meeting Posted 8:55 AM PST
Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistant Subjects Posted 7:53 AM PST
|
| |
| Wednesday, September 24, 2008 |
|
|
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients Posted 3:09 PM PST
ChemBridge Corporation Enters Into New Discovery Chemistry Strategic Alliance With AstraZeneca Posted 6:40 AM PST
|
| |
| Tuesday, September 23, 2008 |
|
|
Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07803, Its Novel Product Candidate for the Treatment of Type 2 Diabetes Posted 4:37 PM PST
Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing Posted 2:54 PM PST
Ebioscience Expands Multicolor Cellular Analysis Portfolio With Introduction of eFluor Brand and Commercial Launch of eFluor Nanocrystal Product Line Posted 8:52 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
